InventisBio (SHA:688382) plans to launch an initial public offering on the main board of the Hong Kong Stock Exchange, according to a Shanghai Stock Exchange filing on Wednesday.
The Chinese biotech firm's board approved the plan on Monday.
InventisBio said the move is aimed at enhancing its capital strength and better utilizing the diversified financing channels of the international capital market.
The planned IPO is subject to approval from regulators in China and Hong Kong and the Hong Kong bourse operator.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments